• Venus Concept Inc. (NASDAQ:VERO) is facing a pessimistic outlook with a potential downside of approximately -48.33%.
• Establishment Labs Holdings Inc. (NASDAQ:ESTA) showcases a significant growth potential with a potential upside of 70.62%.
• AxoGen, Inc. (NASDAQ:AXGN) offers a modest growth outlook with a potential upside of 6.77%.

Venus Concept Inc. (NASDAQ:VERO) specializes in medical aesthetic technology, providing non-invasive and minimally invasive devices for aesthetic and medical applications. Despite its innovative offerings, VERO is currently trading at $3.18, with a target price of $1.64, indicating a potential downside of approximately -48.33%. This gap between the current and target prices reflects a pessimistic outlook from investment analysts, leading to its exclusion from coverage.

In contrast, Establishment Labs Holdings Inc. (NASDAQ:ESTA), a peer in the medical technology sector, is trading at $38 with a discounted cash flow (DCF) valuation of $64.84. This suggests a potential upside of 70.62%, highlighting its strong growth potential. ESTA's focus on breast aesthetics and reconstruction has positioned it as a leader in its niche, offering promising returns for investors.

AxoGen, Inc. (NASDAQ:AXGN), another peer, is trading at $10.92 with a DCF valuation of $11.66. This indicates a modest potential upside of 6.77%. AxoGen specializes in surgical solutions for peripheral nerve injuries, providing a steady growth outlook compared to its peers. While its potential upside is not as high as ESTA's, it still presents a positive investment opportunity.

Among these peers, Establishment Labs Holdings Inc. (ESTA) stands out with the highest target price change and growth potential of 70.62%. This significant upside reflects the company's strong market position and innovative product offerings in the medical aesthetics industry. Investors may find ESTA's growth prospects more appealing compared to VERO and AXGN.